SCHEMBL1944960

SCHEMBL1944960

FC(F)(F)c1cccc(-c2cn3nc(NCCc4ccncc4)sc3n2)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F2RL3 Q96RI0 3/20 0.54
EPHB4 P54760 10/20 0.49
FYN P06241 7/20 0.45
KDR P35968 2/20 0.41
ABL1 P00519 1/20 0.41
EGFR P00533 1/20 0.41
PRKCB P05771 1/20 0.41
INSR P06213 1/20 0.41
LCK P06239 1/20 0.41
LYN P07948 1/20 0.41
PDGFRB P09619 1/20 0.41
SRC P12931 1/20 0.41
PRKCA P17252 1/20 0.41
FLT1 P17948 1/20 0.41
FGFR4 P22455 1/20 0.41
EPHA2 P29317 1/20 0.41
AKT1 P31749 1/20 0.41
FLT4 P35916 1/20 0.41
FLT3 P36888 1/20 0.41
ZAP70 P43403 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1945387 0.87 F2RL3 (0.52) F2RL3EPHB4FYN
SCHEMBL1945470 0.86 NAMPT (0.44) F2RL3EPHB4FYNKDRFLT1
SCHEMBL1948011 0.86 CA12 (0.53) F2RL3FYN
SCHEMBL1946575 0.85 F2RL3 (0.52) F2RL3EPHB4FYN
SCHEMBL1944571 0.85 F2RL3 (0.52) F2RL3EPHB4SYK
SCHEMBL1944643 0.85 TP53 (0.53) F2RL3FYN
SCHEMBL1945484 0.83 FYN (0.58) F2RL3FYN
SCHEMBL1946118 0.83 FYN (0.48) F2RL3FYNGSK3B
SCHEMBL1651219 0.83 FYN (0.55) F2RL3EPHB4FYNKDRABL1
SCHEMBL1945905 0.83 FYN (0.51) F2RL3FYN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2307425-B1 IMIDAZOTHIADIAZOLES DERIVATIVES MERCK PATENT GMBH (DE) 2014-03-26 EP claimed
EP-2307425-B1 IMIDAZOTHIADIAZOLES DERIVATIVES MERCK PATENT GMBH (DE) 2014-03-26 EP disclosed
US-8389554-B2 Imidazothiadiazole derivatives MERCK Patent Gesellschaft mit beschränkter Haftung (DE) 2013-03-05 US disclosed
US-20110130396-A1 IMIDAZOTHIADIAZOLE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2011-06-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110130396-A1 IMIDAZOTHIADIAZOLE DERIVATIVES TGFBR1, TGFBR2, IGF1R F2RL3 1121/4885EPHB4 1627/4885FYN 1977/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.